HemaSphere (Jun 2022)

PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE

  • H. Elsabah,
  • N. Kassem,
  • A. Gulied,
  • R. Taha,
  • H. Elomri,
  • H. Cherif

DOI
https://doi.org/10.1097/01.HS9.0000850820.70181.23
Journal volume & issue
Vol. 6
pp. 1868 – 1869

Abstract

Read online

No abstracts available.